Or
Orchard (Kyowa)
London UKFounded 2015200 employees
Private CapbiotechAcquiredRare Disease
Platform: OTL-200 HSC
Market Cap
N/A
All Drugs
4
Clinical Trials
11
Failed / Terminated
2
FDA Approved
1
Drug Pipeline (4 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| Semaglumide | ORC-8613 | Phase 3 | 3 | SGLT2 | MyelofibrosisEndometrial Ca | ||
| ORC-9172 | ORC-9172 | Phase 3 | 4 | C5 | OCD | ||
| Motasacituzumab | ORC-4786 | Approved | 2 | CDK4/6 | MG | ||
| ORC-2834 | ORC-2834 | Phase 2/3 | 2 | LAG-3 | GBMOvarian Ca |
Financial Documents
This company has been acquired — see parent company for financial filings.
Catalyst Events (11)